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Abstract
Background Stand-alone laparoscopic sleeve gastrectomy
(LSG) has been found to be effective in producing weight loss
but few large, one-center LSG series have been reported.
Gastric leakage from the staple line is a life-threatening com-
plication of LSG, but there is controversy about whether
buttressing the staple line with a reinforcement material will
reduce leaks.We describe a single-center, 518-patient series of
LSG procedures in which a synthetic buttressing material
Reinforcement) was used in the most recently treated patients.
Methods We retrospectively reviewed the medical records of
all patients who underwent LSG in our unit between
September 2007 and December 2011. Patients treated before
August 2009 did not receive the staple line reinforcement
material (n=186), whereas all patients treated afterward did
(n=332).
Results The percentages of excess weight loss in the
518 patients (mean age, 41 years; 82 % female; mean
preoperative body mass index, 44 kg/m2) were 67 %
(79 % follow-up rate) at 6 months postoperatively,
81 % (64 %) at 1 year, and 84 % (30 %) at 2 years.
Type 2 diabetes resolved in 71 % of patients (91/128).
Patients given reinforcement material had baseline char-
acteristics similar to those in the no-reinforcement-
material group, but had no postoperative staple line
leaks or bleeding. The no-reinforcement group had three
leaks (p=0.045) and one case of bleeding.
Conclusions LSG resulted in substantial short-term weight
loss. Use of the bioabsorbable staple line reinforcement ma-
terial may decrease leaks after LSG.
Keywords Obesity . Sleeve gastrectomy . Staple line leak .
Staple line reinforcement . Polyglycolic acid/trimethylene car-
bonate . Bioabsorbable
Introduction
Laparoscopic sleeve gastrectomy (LSG) is a treatment for
obesity that involves removal of the fundus and most of the
antrum of the stomach, thereby creating a gastric tube or
sleeve that restricts oral intake. Several recent randomized
studies [1–5], nonrandomized comparison investigations
[6–9], and analyses of registries [10, 11] and large series [12,
13] have found that use of LSG as a stand-alone procedure is
safe and effective in achieving weight loss. Postsurgical reso-
lution of comorbid conditions such as type 2 diabetes mellitus
(T2DM) and hypertension have also been reported [2, 14–20].
Advantages of LSG over other types of bariatric surgery
include its relative technical simplicity, preservation of the
pylorus, and avoidance of postoperative malabsorption [3,
14, 21]. The popularity of LSG among surgeons and patients
continues to increase.
The reported percentage of excess weight loss (%EWL)
after LSG has varied widely, partly because of differences in
the duration of follow-up and number of patients followed. A
2012 systematic review of 123 articles (covering 12,129 pa-
tients) found that mean %EWL is about 60 % (range, 30–
83 %) at 1 year after surgery and 65 % (range, 46–75 %) at
2 years [22]. An assessment of questionnaire responses (cov-
ering 19,605 procedures) by the Third International Summit
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on LSG yielded similar results, with mean %EWL values of
63 and 65 %, respectively, at 1 and 2 years postoperatively
[21].
Although bariatric surgery is considered safe, it has risks,
with the most serious being gastric leakage from the staple
line. Possible sequelae of a staple line leak include abdominal
sepsis, chronic gastric fistula, multiorgan failure, and death
[23]. The leading cause of death after LSG is staple line
leakage [23]. Fortunately, leak rates are low, with commonly
reported mean values ranging from 1 to 3 % [1, 11, 19,
23–26], although rates up to 10 % have been observed [25].
Bleeding from the staple line can also occur after LSG, in
perhaps 1 to 2 % of patients [4, 5]. This complication is
usually less serious than a staple line leak, but it can result in
financial costs and patient discomfort associated with blood
transfusion or re-exploration [27].
Reinforcement of the staple line has been proposed as a
method for preventing leaks and bleeding after LSG. Methods
of reinforcement include oversewing the staple line, applying
a fibrin sealant, and using a buttressing material. Several
buttressing materials are available, but the most widely used
are a synthetic bioabsorbable material composed of the copol-
ymer polyglycolic acid/trimethylene carbonate (PGA/TMC)
Reinforcement, W.L. Gore & Associates, Elkton, MD, USA)
and bovine pericardium. A recent meta-analysis found that for
55 publications (covering 6,578 patients) in which staple line
buttressing practices in LSG were described, some kind of
buttressing material was used in 82 % of cases and
bioabsorbable buttressing material was employed in 56 %
[26]. The meta-analysis also observed that use of a
bioabsorbable buttressing material reduced the leak rate from
3.2 to 2 %, although the decrease was not statistically signif-
icant. In addition, three small randomized clinical trials (n=40
[28], 25 [29], and 40 [30], respectively, in each treatment arm)
found no significant difference in leak rate between patients
given the PGA/TMC reinforcement material and those in
whom either oversewing [28–30], bovine pericardium [30],
or no reinforcement [29] was used. However, the PGA/TMC
group had a 0 % leak rate in one of those studies [30] and a
significantly lower amount of blood loss (p=0.03) in another
[29].
In contrast to the results of these trials, a meta-analysis by
Choi et al. [31] (covering 1,335 patients) and a 230-patient
series by Daskalakis et al. [32] showed that use of staple line
reinforcement significantly decreased the rate of postoperative
leaks, hemorrhage, or both. Moreover, in a nonrandomized
comparison study (118 total patients), Ser et al. [33] found that
staple line reinforcement significantly reduced postoperative
leaks (to 0 %) compared with no reinforcement (p=0.004).
Saul et al. [34] reported no leaks with use of the PGA/TMC
reinforcement material in an LSG series at a Veterans Affairs
medical center. Finally, an evaluation of the Spanish National
Registry of 540 LSG procedures found that patients in whom
staple line reinforcement was used had a significantly lower
rate of postoperative complications (p=0.039) and a leak rate
which was half that in patients given no reinforcement (2.6 vs
5.3 %) [10].
Aside from staple line leaks and bleeding, issues pertaining
to LSG that have been the focus of many research efforts
include the optimal bougie size and distance from the pylorus
at which gastric division should begin. The Spanish registry
data indicated that use of a smaller bougie (32 F–36 F) was
associated with better weight-loss outcomes at 1 year postop-
eratively, without an increase in complications [10]. In their
meta-analysis, Parikh et al. [26] found no significant differ-
ence between bougies smaller than 40 F and those 40 F or
larger with respect to weight loss up to 1 year, but they did
observe a significantly higher leak rate with smaller bougies
(p=0.0009) that was presumably related to an increase in
intraluminal pressure. Gagner [35] noted that avoiding leaks
depends on using a bougie of at least 50 F.
The evaluation of the Spanish registry data found that
beginning the gastrectomy close to the pylorus resulted in
better weight loss [10]. Bellanger and Greenway [13]
commented that starting the resection 3 to 4 cm from the
pylorus decreases the antral volume while preserving its func-
tion, thereby reducing the risk of distal stricture and proximal
leaks. Others prefer to begin the resection more than 4 cm
from the pylorus with the aim of preserving the gastric antrum
and improving gastric emptying [36].
The variations in results of studies addressing staple line
reinforcement, bougie size, and distance from the pylorus in
LSG indicate clearly that more research on the technical
aspects of the procedure is required. We describe a large




All patients provided informed consent to treatment. Data
was acquired from a retrospective review of the records of
patients who underwent LSG at our center between September
2007 and December 2011. Preoperative patient characteristics
(age, sex, weight, body mass index [BMI], comorbid condi-
tions, and previous bariatric surgery); operative factors (oper-
ating time, concomitant procedures, and bougie size); and
intraoperative and postoperative adverse events, including
staple line leaks, were recorded. Patients who were lost to
follow-up were included only in the assessments of surgical
morbidity and immediate postoperative complications, not in
the weight-loss analyses.
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Before their LSG procedure, patients were advised to quit
smoking and to consume a very-low-calorie diet for a period
ranging from 1 week to 2 months. Patients were also expected
to lose about 10 % of excess weight preoperatively.
Staple line reinforcement material was not used in the 186
patients who underwent surgery before August 2009 (no-rein-
forcement-material group) because it was unavailable. In
August 2009, as part of our ongoing efforts to prevent leaks
by exploring promising new surgical techniques, we began to
use the bioabsorbable PGA/TMCmaterial to buttress the staple
line in all patients (reinforcement-material group; 332 patients).
All patients were scheduled to return for a follow-up visit
with their surgeon 3 months, 6 months, 1 year, 1.5 years, and
2 years postoperatively. Follow-up evaluations included cal-
culation of %EWL and assessments to determine whether
T2DM and hypertension had resolved or improved in patients
who had these conditions preoperatively. The %EWL was
calculated as follows: (preoperative weight minus postopera-
tive weight) / preoperative excess weight times 100.
Preoperative excess weight was calculated as follows: preop-
erative weight minus ideal weight (based on a BMI of 25).
Fourteen percent of the follow-up evaluations for %EWL
were conducted by telephone. An improvement in hyperten-
sion or T2DM was defined as a reduction in the dosage or
number of medications taken to control these conditions; a
resolution of hypertension or T2DM was defined as complete
discontinuation of all therapeutic agents with maintenance of
normoglycaemia.
Surgical Technique
All LSG operations were accomplished laparoscopically; no
conversions to an open procedure were required. An optical
trocar was placed in the left upper quadrant. A 5-mm port was
inserted in the left subcostal area; a 15-mm port was placed in
the right side of the abdomen, in the midclavicular line; and a
12-mm port was inserted in the epigastrium. A Nathanson
retractor was used to lift the left lobe of the liver to provide full
access to the upper stomach. The short gastric vessels were
divided with a Harmonic scalpel (Ethicon Endo-Surgery,
Cincinnati, OH, USA). The dissection was done from the
pyloric region to the left crus. The left crus was fully dissected
until the right crus became visible to allow identification of
any hiatal hernia (HH). A bougie was then inserted to gauge
the new stomach. The first two firings of the Echelon 60
Endopath stapler (Ethicon Endo-Surgery) were done from
the port on the right side; the remaining firings were done
through the epigastric port, toward the gastroesophageal junc-
tion (GEJ) but keeping slightly away from it in order to avoid
injury to the cardia.
Gastric resections were begun 2 to 4 cm from the pylorus.
In the early part of the series (no-reinforcement-material
group), only 40 F bougies were used. Subsequently
(reinforcement-material group), the bougie size ranged from
32 F to 40 F, but a 36 F bougie was used in almost half of the
operations (174). Stapling was done with green reloads. In
patients in whom the bioabsorbable PGA/TMC material was
not used, either oversewing or both oversewing and fibrin
sealant (Tisseel, Baxter, Deerfield, IL, USA) were applied to
the staple line. In patients given the PGA/TMC material,
“figure-of-eight” stitches were placed at intersections so that
the entire staple line became one unit. Moreover, in all pa-
tients, the gastrosplenic ligament was attached to the new
stomach by placing sutures at the intersections of the staple
line with the aim of further securing the staple line and
preventing “spiraling” of the new stomach. Any HH found
was repaired by placement of nonabsorbable monofilament
polybutester sutures (Novafil, Covidien, Mansfield, MA,
USA) either posteriorly, anteriorly, or both. Novafil sutures
were also used to repair the phrenogastric ligament if it had
been divided during the dissection. After hemostasis was
achieved, fibrin sealant was sprayed on the staple line. In most
cases, a Blake drain was inserted and removed on the second
postoperative day.
In the first 186 patients in the series (no-reinforcement-
material group), a methylene blue leak test was performed
before discharge from the hospital. In the reinforcement-
material group, an intraoperative leak test using either meth-
ylene blue or the air-bubble method was initially performed
routinely. However, testing for leaks intraoperatively and in
the immediate postoperative period was subsequently
discontinued because of the poor yield of the assessments:
all staple line leaks in the series occurred after hospital dis-
charge. In addition, many patients had pain at the drain site or
in their left shoulder, and this was observed to subside imme-
diately after drain removal.
Postoperative Care
Patients received morphine only on the day of surgery; sub-
sequently, intravenous paracetamol and indomethacin suppos-
itories were used for pain relief. Intravenous antibiotics were
administered prophylactically for 2 days after surgery, and
intravenous fluids were continued until hospital discharge.
Only patients who had obstructive sleep apnea or a serious
medical problem were admitted to the intensive care unit for
close monitoring (for one night) postoperatively.
Patients began to consume a clear-fluid diet the day after
surgery and progressed to a full-fluid diet before discharge.
They continued the full-fluid diet until their visit with a
dietitian 2 weeks postoperatively, after which they switched
to a mashed/blended diet for about 2 weeks. Most patients
started to consume solid food by 5 or 6 weeks after LSG. They
visited the dietitian again at this time and were encouraged to
eat five or six small, protein-rich meals a day and to drink low-
calorie liquids between meals. In addition, administration of a
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proton-pump inhibitor was begun and continued for 6 months
and lifelong multivitamin supplementation was prescribed.
Patients were also seen by an exercise physiologist
before surgery and 5 weeks afterward to establish an
exercise plan. This plan and the patients’ compliance with
it were subsequently reviewed as needed. Moreover, a
psychology consultation was obtained before surgery to
assess patients’ psychological readiness for LSG, and
postoperative follow-up visits were made on an as-needed
basis.
Data Analysis
Data were entered into a database and compiled. Results are
presented as either numbers and percentages or means ± SD.
Comparisons between the no-reinforcement-material group
and the reinforcement-material group were done by using t
test or Fisher exact test. A p value of less than 0.05 was
considered to represent a significant difference between
groups. All statistical analyses used JMP software (version
8.0.1, SAS Institute, Cary, NC, USA).
Results
Table 1 shows baseline characteristics of the 518 patients who
underwent LSG. Adverse events that occurred perioperatively
or during follow-up are shown in Table 2. The overall adverse-
event rate was 1.7 %; the staple line leak rate was 0.6 %. One
patient had onset of gastroesophageal reflux disease (GERD)
with persistent belching. When conservative treatment did not
resolve this problem, the patient underwent gastric bypass,
which was successful. All three staple line leaks in the series
were observed on the sixth postoperative day. Two leaks were
at the GEJ; the other was near the antrum. One of the patients
in whom a leak occurred died (0.2 % series mortality rate) of
sepsis and multiple organ failure 9 months following LSG,
after six laparotomies, stent placement, and use of total par-
enteral nutrition failed to resolve the leak. The other two
patients with a staple line leak underwent stent placement,
and the leaks resolved at 6 weeks and 5 months, respectively,
after LSG.
One patient in the series had a leak that was not at the staple
line but originated from a gastropexy stitch placed to secure
the stomach and prevent sliding (the patient had a large HH).
The suture broke and a small fistula formed. A laparoscopic
examination performed 7 days postoperatively revealed the
leak, after computed tomographic scanning failed to detect it.
The leak was treated by performing a suture repair covered
with an omental patch and sprayed with fibrin glue, but it
recurred in 4 days. The patient then underwent laparoscopy,
washout, and placement of additional drains around the leak
site, resolving by about 5 months.
Data on weight loss were collected from 79 % of the
patients (n=409) in the series at 6 months postoperatively,
70 % (n=329) at 1 year, and 77 % (n=258) at 2 years. The
%EWL in the short term was 67.1 % at 6 months, 81.2 % at
1 year, and 83.8 % at 2 years. During follow-up, T2DM
resolved completely in 91 of 128 patients (71 %) and im-
proved in 23 (18 %). Hypertension resolved in 64 of 165
patients (39 %) and improved in 54 (33 %).
Table 3 shows baseline, operative, and adverse-events data
in the study, according to whether the bioabsorbable staple
line reinforcement material was used during LSG. There were
no significant differences between the reinforcement-material
group and the no-reinforcement-material group in the patients’
demographic characteristics or the overall postoperative
adverse-event rate. In the no-reinforcement-material group,
one patient had persistent GERD and distressing burping after
LSG, one had an infected hematoma, one had bleeding re-
quiring laparotomy, and three had a staple line leak. In the
reinforcement-material group, there was one leak from a bro-
ken gastropexy stitch, one infected hematoma, one partial
splenic infarction, and no staple line leaks or hemorrhages.
The difference between the groups with respect to staple line
leaks was significant (p=0.045). The reinforcement-material
group also had a significantly shorter operating time and
smaller bougie size, as well as a significantly higher rate of
HH repairs.
Table 1 Baseline characteristics of 518 patients who underwent LSG
Characteristic Value
Mean ± SD age (range), years 40.9±10.7 (17–65)
Female/male, n (%) 425 (82)/93 (18)
Mean ± SD preoperative weight (range), kg 118.4±24.1 (73–214)
Mean ± SD preoperative BMI (range), kg/m2 43.9±7.6 (30–78)
Type 2 diabetes mellitus, n (%) 128 (25)
Hypertension, n (%) 165 (32)
Previous bariatric surgery, n (%) 19 (4)
LSG laparoscopic sleeve gastrectomy, BMI body mass index
Table 2 Adverse events after LSG in 518 patients
Complication Number (%)
Deatha 1 (0.2)
Staple line leak 3 (0.6)
Partial splenic infarction 1 (0.2)
Postoperative bleeding 1 (0.2)
Infected hematoma 2 (0.4)
Leak through broken gastropexy stitch 1 (0.2)
LSG laparoscopic sleeve gastrectomy
a Caused by sepsis and multiple-organ failure 9 months following LSG
and after several unsuccessful attempts to resolve a staple line leak
1112 OBES SURG (2014) 24:1109–1116
Discussion
In this series, we observed values for postoperative %EWL
that are among the highest reported in the literature (Table 4).
Moreover, complete resolution of T2DM occurred after LSG
in more than two thirds of patients who had the condition
preoperatively and hypertension resolved in nearly 40 %. The
operative and postoperative adverse-event rates, including the
rate of staple line leaks, were low. There were no staple line
leaks in the 332 patients given the synthetic bioabsorbable
PGA/TMC staple line reinforcement material, even though
the stomach resection was begun close to the pylorus and
bougies smaller than 40 F were employed. Like others [10,
13, 15], we believe that use of a smaller bougie produces
greater weight loss, but we are aware that employing a small
bougie may increase the risk of staple line leaks caused by an
increase in intraluminal pressure, especially at the angle of His
[35, 41]. However, our results provide new evidence that
using the PGA/TMC reinforcement material mitigates that
risk. Our findings support those of previous LSG series in
which low leak rates (or no leaks) were observed in patients in
whom both this material and a small bougie were used. These
series include those of Gluck et al. (no leaks; 34 F) [39],
Jacobs et al. (1.3 % leak rate; 36 F in 153 patients) [38], and
Saul et al. (no leaks; 34 F) [34]. On the other hand, Bellanger
and Greenway [13] used a 34 F bougie, applied only fibrin
glue to the staple line, and had no leaks in 529 patients.
Aside from having no staple line leaks, our patients who
were given the bioabsorbable reinforcement material had
no bleeding from the staple line. A significant reduction in
bleeding with this material compared with no buttressing or
oversewing the staple line during LSG was previously
reported by Dapri et al. [29] and Consten et al. [27].
Moreover, the 2012 consensus statement on best practices
from the International Sleeve Gastrectomy Expert Panel,
which was based on experience with more than 12,000
cases, included a 100 % agreement with the consensus
point, “Staple line reinforcement will reduce bleeding
along the staple line” [41]. The mechanism by which use
of staple line reinforcement material decreases the risk of
staple line bleeding is unknown, but may be related to the
compressive effect of the material on the transected tissue
[27, 42].
Our results also support those of previous investigations
which found that applying staple line reinforcement material
significantly reduced operating time compared with the time
required for oversewing [28–30]. In our series, the mean
operating time was about 13 min shorter in patients given
the material.
The limitations of our study include its nonrandomized,
retrospective nature and its relatively short follow-up du-
ration. However, new, sufficiently powered randomized
trials comparing the effects of methods of buttressing,
including no buttressing, on staple line leaks after LSG
are unlikely to be performed for two principal reasons.
One is that staple line leak rates are so low that perhaps
as many as 10,000 patients would have to be enrolled
in each treatment arm for a difference between tech-
niques to be discerned [36]. The other is that most
surgeons apparently already routinely use some type of
buttress, especially bioabsorbable reinforcement material
[26], during LSG, and they may therefore have concerns
about withholding the material to fulfill randomization
requirements.
Although the %EWL values in our series were high, a
longer follow-up will be required to assess the effects of our
LSG technique more definitively. Indeed, partly because
stand-alone LSG is a relatively new procedure, there remains
a general paucity of solid long-term data on its effectiveness
with respect to weight loss, alleviation of comorbid condi-
tions, and the need for additional obesity therapy, as well as its
possible association with undesirable postoperative
Table 3 Baseline, operative, and
adverse-events data in patients in
whom the staple line was rein-
forced (n=332) and not rein-
forced (n=186) with reinforce-
ment material







Mean ± SD age, years 40.3±11 41.8±11 0.13
Female/male, n (%) 277 (83)/55 (17) 148 (80)/38 (20) 0.28
Mean ± SD preoperative BMI, kg/m2 44.5±7.5 44.6±7.7 0.1
Previous bariatric surgery, n (%) 15 (4.5) 4 (2.2) 0.22
Mean ± SD operating time, min 72.2±20 85.1±29.2 <0.0001
Mean ± SD bougie size, F 33.5±1.9 40±0 <0.0001
Concomitant HH repair, n (%) 176 (53) 34 (18) <0.0001
Adverse events, n (%) 3 (0.9) 5 (3.2) 0.14
Staple line leaks, n (%) 0 (0) 3 (1.6) 0.045
Leak through broken gastropexy stitch, n
(%)
1 (0.3) 0 (0) 1
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occurrences such as the persistence or onset of GERD.
Overall, the numbers of patients followed for long periods
have been low, and some discrepancies in findings have
appeared. For example, Eid et al. [43] found good mainte-
nance of weight loss in 69 patients followed for 3 to 8 years,
whereas D’Hondt et al. [14] observed a tendency to regain
weight in 23 patients followed for 6 years. Himpens et al. [44]
reported weight regain and new cases of GERD in the interval
3 and 6 years after LSG in 30 patients with long-term follow-
up. Kehagias et al. [40] and Bohdjalian et al. [45] noted a
decline in %EWL weight loss to about 56 % at 5 years
postoperatively in 27 and 26 patients, respectively, but con-
sidered these results satisfactory for their patient populations.
Jiménez et al. [17] found that the T2DM recurrence rate (after
initial remission) was 16% in about 50 patients followed for 2
to 5 years after LSG; not surprisingly, recurrence was associ-
ated with a low %EWL.
Conclusions
In a 518-patient series, LSG performed by using a bougie that
was 40 F or smaller and limiting the antrum size to 2 to 4 cm
resulted in excellent short-term %EWL results at 6 months
and 1 and 2 years after surgery, with few adverse events. In
addition, resolution of or improvement in T2DM and hyper-
tension occurred in 89 and 72 % patients, respectively.
Patients in whom synthetic PGA/TMC staple line reinforce-
ment material was applied during LSG had no postoperative
leaks or hemorrhages from the staple line. The difference in
leak rate between the reinforcement-material group and the
no-reinforcement-material group was significant (p=0.045).
Long-term follow-up in large series can provide important
data on sustained weight loss and other health outcomes in
patients who have undergone LSG.
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